Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2620-2628

  Nishiyama, Masahiko ^a   Yamamoto, Wataru ^a   Park, Ji Seon ^a   Okamoto, Ryo ^a   Hanaoka, Hoken ^a   Takano, Hiroshi ^a   Saito, Norio ^b   Matsukawa, Masaaki ^d   Shirasaka, Tetsuhiko ^c   Kurihara, Minoru ^d  

^a HIROSHIMA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

^d SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GLUTATHIONE TRANSFERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, RENAL CELL; CISPLATIN; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; K562 CELLS; KIDNEY NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OXIDOREDUCTASES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0032837081     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Scanlon, K. J., Newman, E. M., Lu, Y., and Priest, D. G. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA, 83: 8923-8925, 1986.
2. Lacave, J. M., Baron, F. J., Anton, L. M., Estrada, E., De-Sande, J. M. G., Palacio, I., Esteban, E., Gracia, J. M., Buesa, J. M., Fernandez, O. A., and Baron, M. G. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a Phase II trial. Ann. Oncol., 2: 751-754, 1991.
3. Ahlgren, J. D., Trocki, O., Gullo, J. J., Goldberg, R., Muir, W. A., Sosk, R., and Schacter, L. Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. Cancer Investig., 9: 27-33, 1991.
4. Chung, Y. K., Yamashita, Y., Inoue, T., Matsuoka, T., Nakata, B., Onoda, N., Maeda, K., Sawada, T., Kato, Y., Shirasaka, T., and Sowa, M. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric cancer. Cancer (Phila.), 80: 1-7, 1997.
5. Esaki, T., Nakano, S., Tatsumoto, T., Kuroki-Migita, M., Mitsugi, K., Nakamura, M., and Niho, Y. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res., 52: 6501-6506, 1992.
6. Johnston, P. G., Geoffrey, F., Drake, J., Voeller, D., Grem, J. L., and Allegra, C. J. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur. J. Cancer, 32A: 2148-2154, 1996.
7. Peters, G. J., and Jansen, G. Resistance to antimetabolites. In: R. L. Schilsky, G. A. Milano, and M. J. Ratain (eds.), Principles of Antineoplastic Drug Development and Pharmacology, pp. 543-585. New York: Marcel Dekker, 1996.
8. Fischel, J. L., Etienne, M. C., Spector, T., Formento, P., Renée, N., and Milano, G. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin. Cancer Res., 1: 991-996, 1995.
9. Okuyama, T., Maehara, Y., Endo, K., Baba, H., Adachi, Y., Kuwano, M., and Sugimachi, K. Expression of glutathione S-transferase-π and sensitivity of human gastric cancer cells to cisplatin. Cancer (Phila.), 74: 1230-1236, 1994.
10. Chu, E., Drake, J. C., Koeller, D. M., Zinn, S., Jamidow, C. A., Yeh, G. C., and Allegra, C. J. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol. Pharmacol., 39: 136-143, 1991.
11. Van Triest, B., Pinedo, H. M., Telleman, F., Van der Milt, C. L., Jansen, G., and Peters, G. J. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression. Biochem. Pharmacol., 53: 1855-1866, 1997.
12. Nishiyama, M., Suzuki, K., Kumazaki, T., Yamamoto, W., Toge, T., Okamura, T., and Kurisu, K. Molecular targeting of mitomycin C chemotherapy. Int. J. Cancer, 72: 649-656, 1997.
13. Ikenaka, K., Shirasaka, T., Kitano, S., and Fujii, S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Jpn. J. Cancer Res., 70: 353-359, 1979.
14. Spears, C. P. In vitro kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res., 42: 450-456, 1982.
15. Diaso, R. B., Beavers, T. L., and Carpenter, J. T. Familial deficiency of dehydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidemia and severe 5-fluorouracil induced cytotoxicity. J. Clin. Investig., 81: 47-51, 1988.
16. Omura, K., Kawakami, K., Kanehira, E., Nagasato, A., Kawashima, S., Tawaraya, K., Watanabe, S., Hirano, K., Shirasaka, T., and Watanabe, Y. The number of 5-fluoro-2′-deoxyuridine-5′-monophosphate binding sites and reduced folate pool in human colorectal carcinoma tissues: changes after tegafur and uracil treatment. Cancer Res., 55: 3897-3901, 1995.
17. Roninson, I. B., Chin, J. E., Choi, K., Gros, P., Housman, D. E., Fojo, A., Shen, D. W., Gottesman, M. M., and Pastan, I. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl. Acad. Sci. USA, 83: 4538-4542, 1986.
18. Cole, S. P., Ghardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M., and Deeley, R. G. Overexpression of a transporter gene in a multi-resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
19. Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S., and Kuwano, M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cells with decreased drug accumulation. Cancer Res., 56: 4124-4129, 1996.
20. Kano, T., Sakai, M., and Muramatsu, M. Structure and expression of a human class π glutathione S-transferase messenger RNA. Cancer Res., 47: 5626-5630, 1987.
21. Jaiswal, A. K., McBride, O. W., Adesnik, M., and Nebert, D. W. Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase. cDNA sequence and localization of gene to chromosome 16. J. Biol. Chem., 263: 13572-13578, 1988.
22. Shephard, E. A., Palmer, C. N., Segall, H. J., and Phillips, I. R. Quantification of cytochrome P450 reductase gene expression in human tissues. Arch. Biochem. Biophys., 294: 168-172, 1992.
23. Gipp, J. J., Chang, C., and Mulcahy, R. T. Cloning and nucleotide sequence of a full length cDNA for human liver γ-glutamylcysteine synthetase. Biochem. Biophys. Res. Commun., 185: 29-35, 1992.
24. Ercolani, L., Florence, B., Denaro, M., and Alexander, M. Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J. Biol. Chem., 265: 15335-15341, 1988.
25. Satta, T., Isobe, K., Yamauchi, M., Nakashima, I., Akiyama, S., Itou, K., Watanabe, T., and Takagi, H. Establishment of drug resistance in human gastric and colon carcinoma xenograft lines. Jpn. J. Cancer Res., 82: 593-598, 1991.
26. Heggie, G. D., Sommadossi, J. P., Cross, D. S., Huster, W. J., and Diasio, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolite in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987.
27. Kirihara, Y., Yamamoto, W., Toge, T., and Nishiyama, M. Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int. J. Oncol., 14: 551-556, 1999.
28. De Vries, E. G. E., Muller, M., Meijer, C., Jansen, P. L. M., and Mulder, N. H. Role of the glutathione S-conjugate pump in cisplatin resistance. J. Natl. Cancer Inst., 87: 537-538, 1995.
29. Kuo, M. T., Bao, J-J., Curley, S. A., Ikeguchi, M., Johnston, D. A., and Ishikawa, T. Frequent coordinated overexpression of the MRP/ GS-X pump and γ-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res., 56: 3632-3644, 1996.
30. Inaba, M., Tanaka, T., and Sawada, H. Increased sensitivity to long-term 5-fluorouracil exposure of human colon cancer HT-29 cells resistant to short-term exposure. Jpn. J. Cancer Res., 89: 323-327, 1998.
31. Sobrero, A. F., Aschele, C., Guglielmi, A. P., Mori, A. M., Melioli, G. G., Rosso, R., and Bertino, J. R. Synergistic and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J. Natl. Cancer Inst., 85: 1937-1944, 1993.
32. Kigawa. J., Minagawa, Y., Cheng, X., and Terakawa, N. γ-Glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin. Cancer Res., 4: 1737-1741, 1998.
33. Hill, B. T., Shellard, S. A., Hosking, L. K., Dempke, W. C., Fichtinger-Schepman, A. M., Tone, T., and Scanlon, K. J. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate. Cancer Res., 52: 3110-3118, 1992.